Journey Medical Corporation Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

INTANGIBLES (Details)

v3.22.1

INTANGIBLES (Details) - USD ($) $ in Millions						12 Months Ended
INTANGIBLES (Details) - USD ($) $ in Millions	May 13, 2021	Mar. 31, 2021	Jan. 01, 2021	Dec. 18, 2020	Jul. 29, 2020	Dec. 31, 2021	Jan. 01, 2022	Jul. 01, 2021	Apr. 01, 2021
Anti-Itch product
Intangibles
Useful life						3 years
Accutane
Intangibles
Useful life						5 years
Asset purchase agreement \| Qbrexza
Intangibles
Upfront fees	$ 12.5
Milestone payments payable		$ 144.0
Percentage of diminution in royalty		50.00%
Age of patients		9 years
Stay period		30 months
Purchase price		$ 12.5
Useful life		7 years
Asset purchase agreement \| Qbrexza \| Royalty payment percentage for first two years
Intangibles
Period of royalty payments		2 years
Asset purchase agreement \| Qbrexza \| Royalty payment percentage for eight years thereafter
Intangibles
Term of royalty		8 years
Asset purchase agreement \| Qbrexza \| Minimum \| Royalty payment percentage for first two years
Intangibles
Percent of royalty payments		30.00%
Asset purchase agreement \| Qbrexza \| Minimum \| Royalty payment percentage for eight years thereafter
Intangibles
Percent of royalty payments		12.00%
Asset purchase agreement \| Qbrexza \| Maximum \| Royalty payment percentage for first two years
Intangibles
Percent of royalty payments		40.00%
Asset purchase agreement \| Qbrexza \| Maximum \| Royalty payment percentage for eight years thereafter
Intangibles
Percent of royalty payments		19.00%
Asset purchase agreement \| Anti-Itch product
Intangibles
Upfront fees			$ 1.8
Milestone payments payable							$ 1.0	$ 0.5	$ 0.5
Amount of expense agreed to pay under the agreement				$ 4.0
Non refundable deposit				$ 0.2
License And Supply agreement With DRL [Member] \| Accutane
Intangibles
Upfront fees					$ 1.0
Milestone payments payable					4.0
Contingent amount payable					17.0
Amount of expense agreed to pay under the agreement					$ 5.0

- Definition

Age of patients

+ References

No definition available.

+ Details

Name:	derm_AgeOfPatients
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of expense agreed to pay under the agreement.

+ References

No definition available.

+ Details

Name:	derm_AmountOfExpenseAgreedToPayUnderAgreement
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of contingent amount payable under asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementContingentAmountPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payments to be paid in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementMilestonePaymentsPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The period of royalty payments in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementPeriodOfRoyaltyPayments
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of upfront fees paid in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementUpfrontFees
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of diminution in royalty in the event of loss of exclusivity due to the introduction of an authorized generic.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementsPercentageOfDiminutionInRoyalty
Namespace Prefix:	derm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of royalty payments in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementsPercentageOfRoyaltyPayments
Namespace Prefix:	derm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementsPurchasePrice
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The period of stay in patent litigation case.

+ References

No definition available.

+ Details

Name:	derm_LossContingencyPeriodOfStay
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of deposit payable under the agreement.

+ References

No definition available.

+ Details

Name:	derm_NonRefundableDepositPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Term of royalty

+ References

No definition available.

+ Details

Name:	derm_TermOfRoyalty
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=derm_AntiItchProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=derm_AccutaneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=derm_QbrexzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=derm_RoyaltyPaymentPercentageForFirstTwoYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=derm_RoyaltyPaymentPercentageForEightYearsThereafterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_LicenseAndSupplyAgreementWithDrlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: